COMMUNIQUÉS West-GlobeNewswire

DBV Technologies Announces Submission of Biologics License Application for Viaskin Peanut to the U.S. Food and Drug Administration
22/10/2018
Montrouge, France, October 22, 2018 DBV Technologies Announces Submission of Biologics License Application for Viaskin Peanut to the U.S. Food and Drug Administration DBV Technologies (Euronext: DB - ISIN: FR0010417345 [...]
DBV Technologies annonce le dépôt de sa demande d'autorisation de mise sur le marché de produit biologique (BLA) pour Viaskin Peanut auprès de la Food and Drug Administration des États-Unis
22/10/2018
Montrouge, France, le 22 octobre (07h30 CEST), 2018 DBV Technologies annonce le dépôt de sa demande d'autorisation de mise sur le marché de produit biologique (BLA) pour Viaskin Peanut auprès de la Food and Drug [...]
Addex Selective mGlu2 PAM ADX71149 Included in Review Highlighting Promising Investigative Drugs for Epilepsy (Review Published in Epilepsia Journal)
22/10/2018
Geneva, Switzerland, 2 October 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that its selective metabotropic glutamate [...]
Medtronic Co-Founder Earl Bakken Passes Away at Age 94
22/10/2018
DUBLIN - October 21, 2018 - Medtronic plc (NYSE:MDT) announced today that its co-founder, Earl E. Bakken, passed away peacefully on October 21, 2018 at his home on Kiholo Bay on the Big Island of Hawaii. He was 94 years [...]
Genmab Announces Positive Topline Results in Phase III CASSIOPEIA Study of Daratumumab in Front Line Multiple Myeloma
21/10/2018
Company Announcement Phase III CASSIOPEIA study of daratumumab in combination with bortezomib, thalidomide and dexamethasone in front line multiple myeloma met the primary endpoint of stringent Complete Response (sCR) [...]
G1 Therapeutics Presents Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin for Treatment of First-Line Small Cell Lung Cancer
21/10/2018
New data analyses highlight myelopreservation and immune system benefits of trilaciclib in combination with chemotherapy Data presented at the European Society for Medical Oncology (ESMO) 2018 Congress RESEARCH TRIANGLE [...]
Loxo Oncology Announces Larotrectinib Clinical Update in Patients with TRK Fusion Cancers at the European Society for Medical Oncology 2018 Congress
21/10/2018
- Median Duration of Response Not Reached With One Year of Additional Follow-up - - 67 Newly Reported TRK Fusion Patients Exhibit 81% ORR - STAMFORD, Conn., Oct. 21, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq [...]
PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-EXPERIENCED RHEUMATOID ARTHRITIS TO BE PRESENTED AT 2018 ACR/ARHP ANNUAL MEETING
21/10/2018
-- FINCH 2 Study Results Demonstrate Significant Improvement in Rheumatoid Arthritis Signs, Symptoms and Health-Related Quality of Life - Chicago, October 21, 2018 0.30 CET - Gilead Sciences, Inc. (Nasdaq: GILD) and [...]
Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress
20/10/2018
PHILADELPHIA and OXFORD, United Kingdom, Oct. 20, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the first [...]
Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone
20/10/2018
In SOLAR-1 trial, BYL719 plus fulvestrant significantly improved PFS and ORR in these patients, following progression on or after an aromatase inhibitor with or without a CDK4/6 inhibitor, vs. fulvestrant alone[1] [...]
INNATE PHARMA : Phase II results from monalizumab/cetuximab in head and neck cancer at ESMO
20/10/2018
INNATE PHARMA ANNOUNCES PHASE II RESULTS FROM MONALIZUMAB AND CETUXIMAB COMBINATION IN HEAD AND NECK CANCER AT THE ESMO 2018 CONGRESS Confirmation of previously reported response rate and new data on durability of [...]
INNATE PHARMA : Résultats de phase II de monalizumab avec cetuximab dans les cancers de la tête et du cou à ESMO
20/10/2018
INNATE PHARMA ANNONCE DES RÉSULTATS DE PHASE II DE LA COMBINAISON DE MONALIZUMAB ET CETUXIMAB DANS LES CANCERS DE LA TÊTE ET DU COU AU CONGRÈS DE L'ESMO 2018 La confirmation du taux de réponse précédemment observé et [...]
Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab) Continues to Show a 70% Overall Response Rate in Advanced Melanoma Patients According to Data Presented Today at the ESMO 2018 Congress
20/10/2018
- 70% overall response rate (33/47 patients) at 2 mg dose of SD-101 includes 17 additional patients - -Progression free survival, response rate in patients with PDL-1 negative tumors and biomarker activity supports [...]
OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer
20/10/2018
Overall Clinical Benefit Rate of 85%, Partial Response Rate of 42% and Progression Free Survival of 5.4 Months Observed in Patients with > 2 Prior Therapies and/or Prior Bevacizumab REDWOOD CITY, Calif., Oct. 20, [...]
TESARO Announces Data Presentations at ESMO 2018 Congress
20/10/2018
Data presented indicate that TSR-042 (anti-PD-1 antibody) is well tolerated and has robust activity in patients with MSI-H endometrial cancer PRIMA safety data for individualized niraparib dose regimen presented Top- [...]
UPDATE – GrandOmics Biosciences Offers Genetic Test Using the Saphyr System for Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD) in China
20/10/2018
SAN DIEGO, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural [...]
Sanofi: FDA approves asthma indication for Dupixent® (dupilumab)
19/10/2018
FDA approves asthma indication for Dupixent ® (dupilumab) Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype Only biologic approved for oral corticosteroid-dependent asthma, [...]
Sanofi : La FDA approuve l'indication de Dupixent® (dupilumab) dans l'asthme
19/10/2018
La FDA approuve l'indication de Dupixent ® (dupilumab) dans l'asthme Seul agent biologique approuvé pour le traitement de l'asthme modéré à sévère à phénotype éosinophilique Seul agent biologique approuvé pour le [...]
Syneos Health Schedules Third Quarter 2018 Earnings Call for Tuesday, November 6, 2018
19/10/2018
RALEIGH, N.C., Oct. 19, 2018 (GLOBE NEWSWIRE) -- Syneos Health TM (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and Contract [...]

Pages